Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares fell 6.8% on Friday . The stock traded as low as $5.22 and last traded at $5.34. 622,677 shares traded hands during trading, an increase of 1% from the average session volume of 618,319 shares. The stock had previously closed at $5.73.
CNAT has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday. ValuEngine downgraded shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. Finally, Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.80.
The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 2.39. The stock has a market capitalization of $156.76 million, a PE ratio of -8.75 and a beta of 1.84.
Several institutional investors have recently bought and sold shares of CNAT. BlackRock Inc. lifted its position in shares of Conatus Pharmaceuticals by 45.4% in the 1st quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares during the last quarter. Artal Group S.A. bought a new position in shares of Conatus Pharmaceuticals in the 3rd quarter worth about $2,900,000. Alambic Investment Management L.P. lifted its position in shares of Conatus Pharmaceuticals by 207.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Paloma Partners Management Co bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $547,000. Finally, LMR Partners LLP bought a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $311,000. Institutional investors own 33.47% of the company’s stock.
About Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Recommended Story: What are the economic characteristics of a bear market?
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.